Drug nanocrystals: four basic prerequisites for formulation development and scale-up

Area of Science:

• Pharmaceutical Sciences
• Nanotechnology
• Drug Delivery

Background:

• Drug nanocrystals have been researched since the 1990s, with six products on the market and numerous others in clinical trials.
• Nanocrystals are carrier-free nanoparticles enabling 100% drug loading, simplifying formulation development and bioavailability studies.
• The U.S. Food and Drug Administration (FDA) classifies drug nanocrystals as new drugs, not generics, enhancing their market potential.

Purpose of the Study:

• To highlight the significance of drug nanocrystals in pharmaceutical development.
• To outline key prerequisites for successful formulation and scale-up of drug nanocrystals.
• To emphasize the advantages of nanocrystal technology in drug delivery.

Main Methods:

• Discussion of process characterization for nanocrystal development.
• Analysis of equipment selection for nanocrystal production.
• Review of robust formulation strategies and stability considerations.

Main Results:

• Nanocrystals offer simplified manufacturing and rational formulation design.
• The potential for 100% drug loading in carrier-free nanoparticles is a key advantage.
• Successful scale-up relies on addressing process characterization, equipment, formulation, and stability.

Conclusions:

• Drug nanocrystals present a rapidly growing sector in nanoparticle systems due to their design and production simplicity.
• Adherence to four basic prerequisites (process characterization, equipment choice, robust formulation, stability) is crucial for optimizing drug nanocrystal development and market success.
• The unique regulatory status and formulation benefits position nanocrystals favorably for future therapeutic applications.